New Partnership With Open-Access Journal Molecular Neurodegeneration Announced By American Health Assistance Foundation

Main Category: Alzheimer's / Dementia
Also Included In: Parkinson's Disease;  Neurology / Neuroscience
Article Date: 23 Jul 2010 - 5:00 PDT

email to a friend   printer friendly   opinions  

The American Health Assistance Foundation (AHAF)has announced a new partnership with BioMed Central's open access journal, Molecular Neurodegeneration (MN) in which the publication will be the official open access journal of AHAF.

The journal publishes peer-reviewed, original scientific research on the causes of neurodegenerative diseases, like Alzheimer's or Parkinson's, and on the pre-clinical testing of potential therapies for these devastating diseases. According to the ISI Web of Knowledge by Thomson Reuters, MN was ranked in the top 16 percent of journals among the 'neurosciences' category.

"This is an important milestone in the history of AHAF to partner with Molecular Neurodegeneration, one of the top journals in neurodegeneration research," said AHAF President and CEO, Stacy Haller. "The open access nature of this peer-reviewed journal will quickly deliver ground-breaking research which may accelerate the discovery of new treatments and cures for neurodegenerative conditions, like Alzheimer's disease."

Guojun Bu, Ph.D., Co-Editor-In-Chief for Molecular Neurodegeneration, Professor of Cell Biology and Neuroscience at Washington University School of Medicine in St. Louis, MO, said, "This agreement will help the journal to more effectively publish cutting-edge research about the mechanisms of neurodegenerative diseases and the development of new diagnoses and therapies. We look forward to continuing to publish high-quality discoveries and broaden our reach in the research community. Having MN as the official journal of AHAF will help us to do just that."

The open-access model strives to overcome barriers by traditional scientific publications that restrict distribution to those who can afford the fees for electronic access (sometimes a charge of $30 per article). The articles published in MN will be free and will not only help patients and healthcare providers stay abreast of the latest progress, but will also enable scientists to rapidly communicate their important research to the global community.

"We are very excited about this partnership," says AHAF's Vice President of Scientific Affairs, Guy Eakin, Ph.D., "Having Molecular Neurodegeneration as the official journal is important to AHAF's long-time history of support for ground-breaking aging research."

Source:
Charlotte Webber
BioMed Central

• Additional
• References
• Citations